Storkus WJ[au] - Search Results

Year	Number of Results
1986	3
1987	1
1989	2
1990	1
1991	2
1992	1
1993	3
1994	5
1995	10
1996	14
1997	7
1998	5
1999	7
2000	8
2001	6
2002	13
2003	8
2004	6
2005	10
2006	5
2007	14
2008	8
2009	7
2010	6
2011	4
2012	6
2013	5
2014	5
2015	2
2016	6
2017	6
2018	2
2019	5
2020	9
2021	12
2022	4

1

Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. Amouzegar A, et al. Among authors: storkus wj. Cancers (Basel). 2021 May 30;13(11):2695. doi: 10.3390/cancers13112695. Cancers (Basel). 2021. PMID: 34070756 Free PMC article. Review.

2

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.

Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Guo ZS, et al. Among authors: storkus wj. J Immunother Cancer. 2019 Jan 9;7(1):6. doi: 10.1186/s40425-018-0495-7. J Immunother Cancer. 2019. PMID: 30626434 Free PMC article. Review.

3

Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.

Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Dai E, et al. Among authors: storkus wj. Mol Cancer. 2021 Dec 20;20(1):171. doi: 10.1186/s12943-021-01464-x. Mol Cancer. 2021. PMID: 34930302 Free PMC article. Review.

4

STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.

Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. Chelvanambi M, et al. Among authors: storkus wj. J Immunother Cancer. 2021 Feb;9(2):e001906. doi: 10.1136/jitc-2020-001906. J Immunother Cancer. 2021. PMID: 33526609 Free PMC article.

5

Thirty years of therapeutic innovation in melanoma research.

Lejeune FJ, Storkus WJ, Riley PA. Lejeune FJ, et al. Among authors: storkus wj. Melanoma Res. 2021 Apr 1;31(2):105-107. doi: 10.1097/CMR.0000000000000723. Melanoma Res. 2021. PMID: 33625105 No abstract available.

6

IL-36 Signaling in the Tumor Microenvironment.

Chelvanambi M, Weinstein AM, Storkus WJ. Chelvanambi M, et al. Among authors: storkus wj. Adv Exp Med Biol. 2020;1240:95-110. doi: 10.1007/978-3-030-38315-2_8. Adv Exp Med Biol. 2020. PMID: 32060891 Free PMC article. Review.

7

Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.

Fabian KL, Storkus WJ. Fabian KL, et al. Among authors: storkus wj. Adv Exp Med Biol. 2017;1036:191-211. doi: 10.1007/978-3-319-67577-0_13. Adv Exp Med Biol. 2017. PMID: 29275473 Review.

8

STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.

Filderman JN, Appleman M, Chelvanambi M, Taylor JL, Storkus WJ. Filderman JN, et al. Among authors: storkus wj. Front Immunol. 2021 May 13;12:690105. doi: 10.3389/fimmu.2021.690105. eCollection 2021. Front Immunol. 2021. PMID: 34054879 Free PMC article. Review.

9

Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment.

Weinstein AM, Storkus WJ. Weinstein AM, et al. Among authors: storkus wj. Adv Cancer Res. 2015;128:197-233. doi: 10.1016/bs.acr.2015.04.003. Epub 2015 May 5. Adv Cancer Res. 2015. PMID: 26216634 Free PMC article. Review.

10

Neoepitopes as Difference Makers for General Cancer Vaccines?

Filderman JN, Storkus WJ. Filderman JN, et al. Among authors: storkus wj. Clin Cancer Res. 2020 Sep 1;26(17):4429-4431. doi: 10.1158/1078-0432.CCR-20-2127. Epub 2020 Jul 9. Clin Cancer Res. 2020. PMID: 32646923 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results